ICER Questions Cost Effectiveness Of Empliciti, Kyprolis, Ninlaro
This article was originally published in The Pink Sheet Daily
Newer regimens for multiple myeloma confer clinical survival benefits, but their cost-to-effectiveness comparisons are unfavorable, group says.
You may also be interested in...
The Institute for Clinical and Economic Review is launching an initiative to adapt its value assessment approach to orphan and ultra-orphan drugs, including a possible consideration of what should be a fair return on investment for manufacturers.
With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.
ICER report finds EGFR inhibitors are cost-effective in first-line non-small cell lung cancer, but PD-1/L1 inhibitors from Bristol, Merck and Roche may fall short in second-line treatment.